Company Overview and News
September 18, 2018: Markets opened higher Tuesday and all three major indexes are on track to post a decent gain for the day. Investors continue to find reasons to downplay the U.S.-China trade spat-soon-become-a-full-fledged-war and focus instead on the strong U.S. economy. The telecom and consumer discretionary stocks were the day’s leading gainers while consumer staples and real estate lagged
NKE CATR CAT BOE INTC BA
On Sep 17, we issued an updated research report on The Manitowoc Company, Inc. (MTW - Free Report) . The company is poised to gain from product innovation, backlog strength, focus on cost control and pricing actions. However, steel tariffs and currency fluctuation might impede the company’s growth. Let’s illustrate the factors in detail. Manitowoc to Gain from Pricing Actions Manitowoc continues to execute its strategy to cover cost inflation through pricing actions.
CATR CAT ATKR IRBT MDPEB MDP MTW
Industrial production climbed for the third straight month in August, as robust growth in automobile manufacturing outpaced lackluster production in other sectors. A better-than-expected upsurge in the headline numbers was also backed by an uptick in mining and utilities output.
FLOW CATR CAT LXFR TKR TRS
Chicago, IL – September 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caterpillar Inc. (CAT - Free Report) , International Paper Company (IP - Free Report) , MetLife, Inc. (MET - Free Report) and Broadcom Limited (AVGO - Free Report) .
CAT MET FNMA FMCKI FMCKJ IP AVGO FMCCO FMCCP FMCCM CATR FMCCN INPAP FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCC BRCM FMCCS FMCCT
After a two-week absence, 3M Co. (NYSE: MMM) dropped once again into the Dow Jones industrials cellar. The industrial giant’s stock lost about 2.2% last week and is now trading down 11.7% for the year to date.
JBK MTSI PG CATR GSC CAT TFG GSJ GS GLSSP GJS MCD MMM
U.S. technology and consumer discretionary stocks have been insulated from global trade tensions, but if another round of U.S. tariffs on Chinese goods goes into effect, even those high-flying sectors could come down to earth.
CATR CAT AMP MAT WHR BOE MSFT MS BA
Industrial giant Caterpillar Inc. (NYSE: CAT) reported August retail sales Friday morning in a filing with the U.S. Securities and Exchange Commission. Total global machine retail sales rose 23% year over year, while energy and transportation sales were up 16% compared with August 2017.
NEW YORK (Reuters) - U.S. technology and consumer discretionary stocks have been insulated from global trade tensions, but if another round of U.S. tariffs on Chinese goods goes into effect, even those high-flying sectors could come down to earth.
CATR CAT AMP MAT WHR BOE MSFT MS BA
After surviving two world wars and 1930’s Great Depression, Lehman Brothers had filed for bankruptcy on Sep 15, 2008. The collapse of the leading investment bank not only affected its employees or investors but also led to a global financial crisis.
CY CAT MET FNMA FMCKI FMCKJ IP AVGO FMCCO FMCCP FMCCM CATR FMCCN INPAP FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCC BRCM FMCCS FMCCT
Caterpillar Inc. CAT, +0.83% reported Friday August machine retail sales that showed further deceleration in growth worldwide, despite continued acceleration in North America. The stock slipped 0.1% in morning trade. On a 3-month rolling basis, total machines sales globally rose 23% in August, after rising 24% in July and 25% in June. In North America, however, sales rose 29% in August, after increasing 27% in July and 22% in June.
Apogee Enterprises, Inc. (APOG - Free Report) is slated to release second-quarter fiscal 2019 results on Sep 18, before the opening bell. In the last reported quarter, Apogee’s earnings beat the Zacks Consensus Estimate. The trailing four-quarter average earnings surprise of the stock is 0.88%. Let’s see how things are shaping up for this announcement.
CATR CY CAT ALRM APOG FLS
September 12, 2018: Markets opened mixed Wednesday and none of the major indexes strayed to far from the break-even line. Today brought the introduction of new hardware from Apple, an event about which more pixels are burned than perhaps any other. The Fed Beige Book also rolled out today with a lot of attention paid to energy. Consumer staples and energy are the day’s best performing staples while financial services and tech stocks lagged.
PG CATR CAT BOE WBA BA
The popularity of value investing is on the rise. The success of billionaire value investors like Warren Buffett further underscores the fact. Over the past five years, his conglomerate Berkshire Hathaway's book value has grown at a compound annual rate of 11% (The Economist). Per a July Motley Fool article last year, over the past 50 years, the stock has yielded a compound annual return of 20.8%. This indicates that an investment of $10,000 in 1965 would be worth $88 million today.
PK BRK.A CATR ARCB CAT CFX PCAR
The Dow 30 — one of the equity markets’ most closely watched indexes — commenced September trading on a negative note after two successful months. After ending in negative territory in the first week of this month, the blue-chip index closed in the green on Sep 11. At present, the index is within striking distance of achieving an all-time high. Despite trade war concerns, a robust U.S. economy and strong earnings results bolstered investors’ confidence in the stock markets enabling the Dow to climb out of the rut.
CATR CAT AAPL MSFT UNH
Chicago, IL –September 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Caterpillar Inc. (CAT - Free Report) , Amazon.com, Inc. (AMZN - Free Report) , Berkshire Hathaway Inc. (BRK.B - Free Report) and Microsoft Corp.
RBBN CAT GS GLSSP AMZN MS JBK CATR GSC TFG CSL GSJ BRK.A MSFT GJS
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to EPA:CATR / CATERPILLAR INC on message board site Silicon Investor.
|DMTN - D Mecatronics, Inc.||DMTN - D Mecatronics, Inc.||DMTN - D Mecatronics, Inc.||Orcatron (OCT.V)||Orcatron (OCT.V)||Orcatron (OCT.V)|